Mereo BioPharma (UK) Insiders
| 0A9G Stock | 3.55 0.15 4.41% |
Mereo BioPharma employs about 33 people. The company is managed by 12 executives with a total tenure of roughly 77 years, averaging almost 6.0 years of service per executive, having 2.75 employees per reported executive. Breaking down Mereo BioPharma's management performance can provide insight into the firm performance.
| Denise ScotsKnight CEO CEO CoFounder |
Mereo |
Mereo BioPharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.3065) % which means that it has lost $0.3065 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7364) %, meaning that it generated substantial loss on money invested by shareholders. Mereo BioPharma's management efficiency ratios could be used to measure how well Mereo BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. Net Tangible Assets is likely to gain to about 45.6 M in 2024, whereas Other Current Assets are likely to drop slightly above 406.3 K in 2024.Net Loss is likely to drop to about (41.3 M) in 2024
Mereo BioPharma Workforce Comparison
Mereo BioPharma Group is number one stock in number of employees category among its peers. The total workforce of Industrials industry is presently estimated at about 9,429. Mereo BioPharma adds roughly 33.0 in number of employees claiming only tiny portion of equities under Industrials industry.
Mereo BioPharma Group Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Mereo BioPharma Group Price Series Summation is a cross summation of Mereo BioPharma price series and its benchmark/peer.
Mereo BioPharma Notable Stakeholders
A Mereo BioPharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mereo BioPharma often face trade-offs trying to please all of them. Mereo BioPharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mereo BioPharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Charles Sermon | General CoFounder | Profile | |
| MBBS MD | CoFounder Strategy | Profile | |
| John MBA | CoFounder Officer | Profile | |
| MBA MBA | CoFounder Officer | Profile | |
| Denise ScotsKnight | CEO CoFounder | Profile | |
| Christine CPA | Chief Officer | Profile | |
| Bo Kara | Senior CMC | Profile | |
| Fiona Bor | Head Property | Profile | |
| John Lewicki | Chief Officer | Profile | |
| Jackie Parkin | Therapy Endocrinology | Profile | |
| Alexandra HughesWilson | Chief Planning | Profile | |
| Suba Krishnan | Senior Development | Profile |
About Mereo BioPharma Management Performance
The success or failure of an entity such as Mereo BioPharma Group often depends on how effective the management is. Mereo BioPharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mereo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mereo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Mereo BioPharma is entity of United Kingdom. It is traded as Stock on LSE exchange.
Please note, the imprecision that can be found in Mereo BioPharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mereo BioPharma Group. Check Mereo BioPharma's Beneish M Score to see the likelihood of Mereo BioPharma's management manipulating its earnings.
Mereo BioPharma Workforce Analysis
Traditionally, organizations such as Mereo BioPharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mereo BioPharma within its industry.Mereo BioPharma Manpower Efficiency
Return on Mereo BioPharma Manpower
| Revenue Per Employee | 30.3K | |
| Revenue Per Executive | 83.3K | |
| Net Loss Per Employee | 1M | |
| Net Loss Per Executive | 2.8M |
Additional Tools for Mereo Stock Analysis
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.